MAIN ARTICLE
The numbers behind the headline
TRANSCEND-T2D-2 enrolled 1,298 adults whose type 2 diabetes was inadequately controlled with metformin, with or without an SGLT2 inhibitor. Participants were randomly assigned to weekly retatrutide at 9 mg or 12 mg, or to 2 mg semaglutide, the active ingredient of Ozempic. At 80 weeks, the two investigational doses were associated with average weight reductions of 19.5% and 20.9%, compared with 9.4% for the marketed comparator. These figures use an efficacy analysis estimating outcomes if participants remained on the planned treatment, rather than simply describing every real-world patient who starts it.
HbA1c fell an average of 2.2 percentage points in both retatrutide groups and 1.8 points in the Ozempic group. The gap is potentially clinically meaningful, but averages cannot predict an individual response. Lilly has published headline findings; the comprehensive analysis has yet to be presented at a medical meeting and published after peer review.
Why three receptors matter
Ozempic acts on the GLP-1 receptor, whereas retatrutide targets GLP-1, GIP and glucagon receptors. The combination is designed to influence appetite, glucose regulation and energy use in complementary ways.

















